References
- Jemal A, Clegg LX, Ward E, et al: Annual report to the nation on the status of cancer; 1975-2001, with a special feature regarding survival. Cancer. 2004;101:3-27 https://doi.org/10.1002/cncr.20288
- Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature. 2001;411:355-365 https://doi.org/10.1038/35077225
- Roskoski R Jr: STI-571: an anticancer protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun. 2003;309:709-717 https://doi.org/10.1016/j.bbrc.2003.08.055
- Capdeville R, Buchdunger E, Zimmermann J, Matter A: Glivec (STI571, imatinib ), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002; 1 :493-502 https://doi.org/10.1038/nrd839
- Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925-932
- Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566 https://doi.org/10.1038/nm0596-561
- Hibi K, Takahashi T, Sekido Y, et al: Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene. 1991;6:2291-2296
- Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580 https://doi.org/10.1126/science.279.5350.577
- Vanhaesebroeck B, Alessi DR: The P13K-PDK1 connection: more than just a road to PKB. Biochem J. 2000;346:561-576 https://doi.org/10.1042/0264-6021:3460561
- Stephens LR, Jackson TR, Hawkins PT: Agonist-stimulated synthesis of phosphatidylinositol (3,4,5)-triphosphate: a new intracellular signalling system? Biochim Biophys Acta. 1993;1179: 27-75 https://doi.org/10.1016/0167-4889(93)90072-W
- Amomphimoltham P, Sriuranpong V, Patel V, et al: Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res. 2004; 10:4029-4037 https://doi.org/10.1158/1078-0432.CCR-03-0249
- Cheng JQ, Ruggeri B, Klein WM, et al: Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA. 1996; 93:3636-3641
- Ballacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 1995;64:280-285 https://doi.org/10.1002/ijc.2910640412
- Vivanco I, Sawyers CL: The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nature Rev Cancer. 2002;2:489-501 https://doi.org/10.1038/nrc839
- Grille SJ, Bellacosa A, Upson J, et al: The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 2003;63:2172-2178
- McCormick F: Cancer: survival pathways meet their end. Nature. 2004;428:267-269 https://doi.org/10.1038/428267a
- Basu S, Totty NF, Irwin MS, Sudol M, Downward J: Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell. 2003;11:11-23
- Wendel HG, De Stanchina E, Fridman JS, et al: Survival signalling by Akt and elF4E in oncogenesis and cancer therapy. Nature. 2004;428:332-337 https://doi.org/10.1038/nature02369
- Sawyers CL: Chronic myeloid leukemia. N Engl J Med. 1999; 340:1330-1340 https://doi.org/10.1056/NEJM199904293401706
- Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000; 100:57-70 https://doi.org/10.1016/S0092-8674(00)81683-9